ARTICLE | Company News
Sumitomo, Tolero deal
December 30, 2016 9:08 PM UTC
Sumitomo will acquire Tolero for $200 million up front, up to $430 million in development milestones and up to $150 million in sales milestones. The deal will provide Sumitomo with alvocidib flavopiridol, which has completed a Phase II trial to treat acute myelogenous leukemia (AML), and preclinical anemia candidate TP-0184, an activin receptor-like kinase 2 (ALK2; ACVR1) inhibitor. The acquisition is expected to close in February. ...
BCIQ Target Profiles